Regeneron stock: Q3 revenue rises 36% as Sanofi alliance expands
Published on 11/03/2026 at 14:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth And Sanofi Expansion
- Regeneron's third-quarter revenue reached USD 5.116 billion, while non-GAAP diluted earnings per share rose to USD 20.07.
- The Sanofi alliance now covers four next-generation, long-acting antibodies with equal cost and profit sharing.
- Management expects a USD 1.0 billion upfront payment to enter fourth-quarter collaboration revenue.
- Pasatru received US approval for adults with fibrodysplasia ossificans progressiva.
Regeneron Pharmaceuticals reported on Friday, October 30, that third-quarter 2026 revenue rose 36 percent from a year earlier to USD 5.116 billion. The company also expanded its antibody alliance with Sanofi, adding four next-generation, long-acting programs and setting up a further revenue contribution in the fourth quarter.
The Regeneron release showed GAAP net income of USD 1.949 billion, up 33 percent year over year. Diluted GAAP earnings per share increased 35 percent to USD 18.45, while adjusted diluted earnings per share climbed 70 percent to USD 20.07. Adjusted net income reached USD 2.150 billion, compared with USD 1.287 billion in the prior-year quarter.
Sanofi Deal Broadens Pipeline
Regeneron said the October amendment adds four Regeneron-invented, long-acting antibodies to the Sanofi collaboration. The companies will share development and commercialization costs equally and, if the programs reach the market, split global profits equally. Regeneron received a USD 1.0 billion upfront payment and could receive up to an additional USD 7.0 billion in development, regulatory and sales-based milestones.
The existing business also supported the quarter. Sanofi collaboration revenue increased 68 percent to USD 2.724 billion, including Regeneron's USD 2.575 billion share of antibody commercialization profits versus USD 1.456 billion a year earlier. Dupixent global sales recorded by Sanofi rose 35 percent to USD 6.541 billion. EYLEA HD US sales increased 62 percent to USD 699 million, while global Libtayo sales rose 51 percent to USD 550 million. Combined EYLEA HD and EYLEA sales fell 11 percent to USD 1.741 billion, highlighting the continuing transition away from the older formulation.
Guidance And Pipeline Catalysts
Regeneron raised its full-year 2026 non-GAAP research and development expense outlook to USD 6.050 billion to USD 6.150 billion from USD 5.950 billion to USD 6.050 billion. It lowered the corresponding selling and administrative expense range to USD 2.400 billion to USD 2.500 billion and lifted expected non-GAAP product gross margin to approximately 86 percent.
Chief Executive Leonard Schleifer said the company had about 50 candidates in clinical development and expected an FDA decision on cemdisiran in generalized myasthenia gravis in November. The company also highlighted progress in oncology, obesity, metabolic disease and rare disease programs. Pasatru was approved by the FDA in August for adults with fibrodysplasia ossificans progressiva.
The real-time quote of Regeneron stock traded at 858.70 euros on Lang & Schwarz at 14:05 CET on Tuesday, November 3.
US equities remain the relevant market setting for Regeneron and can be followed in the S&P 500 market overview.
For further company developments, see More news and analyses on Regeneron stock.
Regeneron Pharmaceuticals Key Facts
- Company: Regeneron Pharmaceuticals, Inc.
- ISIN: US75886F1075
- Ticker: REGN
- Primary exchange: Nasdaq
- Lang & Schwarz quote: EUR 858.70 on Tuesday, November 3, 2026, at 14:05 CET
- Third-quarter revenue: USD 5.116 billion, up 36 percent year over year
- Non-GAAP diluted earnings per share: USD 20.07, up 70 percent year over year
- Sanofi upfront payment: USD 1.0 billion expected in fourth-quarter 2026 collaboration revenue
